S. L. Johnston (London, United Kingdom), G. Brusselle (Ghent, Belgium)
Monitoring PGD2 production in airway disease
J. Larsson, D. Balgoma, I. Delin, T. Gülen, G. Nilsson, H. Hägglund, K. Daham, J. Lawson, G. FitzGerald, B. Dahlén, C. Wheelock, S. E. Dahlén (Stockholm, Sweden; Philadelphia, United States Of America)
|  |
Antibiotics in exacerbations of asthma
R. Loijmans, P. van Velzen, L. Beem, M. Stommel, G. ter Riet, P. Sterk (Amsterdam, Netherlands)
|  |
Monitoring free serum IgE in severe asthma patients treated with omalizumab
S. Korn, I. Haasler, F. Fliedner, G. Becher, P. Strohner, A. Staatz, C. Taube, R. Buhl (Mainz, Bernau, Berlin, Germany)
| |
Serum immunoglobulin level is a useful marker for the risk of opportunistic infection in steroid dependent patients with chronic inflammatory airway diseases
M. Akahane, N. Horita, T. Takezawa, T. Arai, M. To, Y. To (Tokyo, Japan)
| |
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
M. Hübner, S. Korn, M. Jung, I. Haasler, C. Taube, R. Buhl (Mainz, Germany)
| |
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
M. L. Torres Duran, J. C. Barros Tizon, Investigators of the Spanish Group for Rexa Study (Vigo, Spain)
| |
Efficacy of roflumilast in the frequent exacerbation COPD phenotype
J. Wedzicha, K. Rabe, P. Calverley, F. Martinez, D. Bredenbröker, M. Brose, U. M. Goehring (London, Liverpool, United Kingdom; Grosshansdorf, Konstanz, Germany; Ann Arbor, United States Of America)
| |
Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD
G. Lahu, A. Facius, L. Claret, R. Bruno, D. Bredenbröker (Konstanz, Germany; Marseilles, France)
| |
Clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease
G. Agmy, Y. Ahmed, S. Helal (Assiut, Egypt)
| |
Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation
H. Tang, Z. Fang, Q. Xiu, on Behalf of the Broncho-Vaxom Study Group (Shanghai, China)
| |
β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD
A. Afonso, K. Verhamme, G. Brusselle, M. Sturkenboom (Rotterdam, Netherlands; Ghent, Belgium)
| |
Skin sensitivity to corticosteroids is associated with COPD susceptibility
S. J. M. Hoonhorst, A. T. Lo Tam Loi, R. G. A. Hiltermann, L. Koenderman, J. W. Lammers, D. S. Postma, N. H. T. ten Hacken (Groningen, Utrecht, Netherlands)
| |
Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial
A. Scherr, J. Anja, S. Salome, D. Miedinger, M. Sabrina, A. Taegtmeyer, C. Prashant, S. Anderson, T. Michael, J. D. Leuppi (Basel, Switzerland; Camperdown, Australia)
| |
Double blind, placebo controlled crossover study in COPD patients to assess the acute effect of budesonide/formoterol using HRCT and lung function tests
L. De Backer, J. De Backer, W. Vos, C. Van Holsbeke, S. Vinchurkar, W. De Backer (Antwerp, Antwerpen, Belgium)
| |
Antibiotic prescription in asthma exacerbations in the admitting and emergency (A&E) department
C. Gouder, J. Farrugia Preca, R. Asciak, J. Micallef, S. Montefort (Birkirkara, Malta)
| |
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
D. Hui, A. Mahayiddin, C. Roa, K. H. Kwa, D. Bredenbröker, U. M. Goehring, H. P. Kuo, S. D. Lee (Shatin, Hong Kong; Kuala Lumpur, Malaysia; Manila, Philippines; Konstanz, Germany; Taipei, Taiwan; Seoul, Republic Of Korea)
| |